Zydus Cadila Group Chairman Pankaj R Patel said this innovation has the potential to bring about a paradigm shift in the management of CKD patients with anaemia.
New Delhi: Drug firm Zydus Cadila Wednesday announced phase III clinical trials of Desidustat, an investigational new drug targeted at treating anaemia in non-dialysis dependent chronic kidney disease patients.
“This phase III study will be a multicenter (50-60 sites), randomised, active-controlled clinical trial to evaluate the efficacy and safety of Desidustat versus Darbepoetin for the treatment of anaemia in patients with chronic kidney disease (CKD) who are not on dialysis,” the company said in a regulatory filing.
Read Also: Zydus Cadila gets tentative USFDA nod to Lacosamide tablets to treat seizures
Zydus Group Chairman Pankaj R Patel said this innovation has the potential to bring about a paradigm shift in the management of CKD patients with anaemia.
Earlier, Desidustat had met its primary endpoints in phase II clinical study of non-dialysis dependent chronic kidney disease patients suffering from anaemia.
The phase I trials were earlier completed in Australia, the company said.
Read Also: Zydus Cadila gets tentative USFDA nod for Mirabegron ER tablets to treat overactive bladder
Farhat Nasim
Latest posts by Farhat Nasim (see all)
- Glenmark Pharma gets USFDA approval for generic version of VAGIFEM - April 25, 2019
- Monarch eTNS: First medical device for treating ADHD gets USFDA approval - April 25, 2019
- Indoco Remedies: USFDA retains OAI status for Goa plant - April 25, 2019
